The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients

Psychopharmacology

Volumn 129, Issue 3, 1997, Pages 285-288

  Riekkinen Jr , Paavo ^a   Soininen, Hilkka ^a   Partanen, Juhani ^a   Pääkkönen, Ari ^a   Helisalmi, Seppo ^a   Riekkinen Sr , Paavo ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Alzheimer disease; Apolipoprotein E; EEG slowing; THA

Indexed keywords

APOLIPOPROTEIN E; TACRINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ALPHA RHYTHM; ALZHEIMER DISEASE; AROUSAL; ARTICLE; BRAIN CORTEX; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; GENOTYPE; HUMAN; MAGNOCELLULAR NUCLEUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TAKIN; THETA RHYTHM;

AGED; ALPHA RHYTHM; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; GENOTYPE; HUMANS; MIDDLE AGED; TACRINE;

EID: 8044226593     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050192     Document Type: Article

References (19)

1. Alhainen K, Partanen J, Reinikainen K, Laulumaa V, Soininen H, Airaksinen M, Riekkinen P (1991) Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease. Neurosci Lett 127:113-116
2. Björklund M, Jäkälä P, Schmidt B, Riekkinen M, Koivisto E, Riekkinen P Jr (1996) An indirect cholinesterase inhibitor, metrifonate, increases neoeortical EEG arousal in rats. NeuroReport (in press)
3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Guskell PC, Small GW, Roses AD, Haines JL, Perieuk-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923
4. Davis KL, Thai LJ, Gamzu ER, Davis SC, Woolfson RE, Gracon SI, Drachman DA, Schneider LS, White-house P, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earl NL, Kumar V, Doody R, Tacrine Collaborative Study Group (1992) A double-blind, placebo-controlled mullicenter study of tacrine for Alzheimer's disease. N Engl J Med 327:1253-1259
5. Gustafson L, Edwinson L, Dahlgren N (1987) Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement and EEG. Psychopharmacology 93:31-35
6. Helkala E-L, Koivisto K, Hänninen T, Vanhanen M, Kervinen K, Kuusisto J, Mykkänen L, Kesäniemi YA, Laakso M, Riekkinen P Sr (1996) Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study. Neurosci Lett 204:177-180
7. Nuwer MR (1988) Quantitative EEG: techniques and problems of frequency analysis and topographic mapping. J Clin Neurophysiol 5:1-43
8. Poirier J (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 17:525-530
9. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinistö L, Halonen P, Kontula K (1995) Apolipoprotein E, dementia, and cortical deposition of B-amyloid protein. N Engl J med 333:1242-1247
10. Reinikainen KJ, Riekkinen P, Paljärvi L, Soininen H, Helkala E-L, Jolkkonen J, Laakso M (1988) Cholinergic deficit in Alzheimer's disease: a study based on autopsy and CSE data. Neuroehem Res 13:135-146
11. Riekkinen P, Buzsáki G, Riekkinen P Jr, Soininen H, Partanen J (1991) The cholinergic system and EEG slow waves. Electroencephalogr Clin Neurophysiol 78:89-96
12. Riekkinen P Jr, Sirviö J, Riekkinen M, Riekkinen P Sr (1991a) Effects of THA on passive avoidance retention performance of intact, nucleus basalis, frontal cortex and nucleus basalis + frontal-lesioned rats. Pharmacol Biochem Behav 39: 841-846
13. Riekkinen P Jr, Sirviö J, Valjakka A, Riekkinen M, Lammintausta R, Riekkinen P (1991b) Effects of alpha2 antagonists and an agonist on EEG slowing induced by scopolamine and lesion of the nucleus basalis. Neuropharmacology 29:993-999
14. Sahakian BJ, Coull JT (1994) Nicotine and tetrahydroaminoacridine: evidence for improved attention in patients with dementia of the Alzheimer type. Drug Dev Res 31:80-88
15. Soininen H, Partanen J, Laulumaa V, Riekkinen P Sr (1991) Serial EEG in Alzheimer's disease: 3 year follow-up and clinical outcome. Electroencephalogr Clin Neurophysiol 79:342-348
16. Soininen H, Reinikainen K, Partanen J, Helkala E-L, Paljärvi L, Riekkinen P Sr (1992) Slowing of electroencephalogram and choline acetyltransferase activity in post mortem frontal cortex in definite Alzheimer's disease. Neuroscience 49:529-535
17. Soininen H, Kosunen O, Helisalmi S, Mannermaa A, Paljärvi L, Talasniemi S, Ryynänen M, Riekkinen P Sr (1995a) A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein E4 allele. Neurosci Lett 187:79-82
18. Soininen H, Partanen K, Pitkänen A, Hallikainen M, Hänninen T, Helisalmi S, Mannermaa A, Ryynänen M, Koivisto K, Riekkinen P Sr (1995b) Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E4 allele. Neurology 45:391
19. Whitehouse P, Price DL, Struble RG, Clark AW, Coyle JT, DeLong RM (1982) Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237-1239